https://biti.uz/konferensiya/konferensiya2025/index.html
21 апреля 2025 г.
401
MAGNETIC RESONANCE IMAGING IN THE DIAGNOSIS AND
CLINICAL EVALUATION OF BRAIN TUMORS: A STUDY BASED IN
UZBEKISTAN
Arshaan Asif Shaikh, Saloni Sajid Maner
Supervisor-: Alisherova Mahliyo Abdunabi Qizi
MD Medicine , Students
Tashkent Medical Academy
Abstract:
Brain tumors present complex diagnostic and therapeutic
challenges, necessitating an integrated approach that combines clinical expertise
with advanced neuroimaging techniques. Magnetic Resonance Imaging (MRI) has
emerged as a cornerstone modality for the evaluation of intracranial neoplasms,
offering non-invasive, high-resolution visualization of brain structures. This study,
conducted at the Republican Specialized Neurosurgery Scientific and Practical
Medical Center in Tashkent, Uzbekistan, aimed to evaluate the diagnostic
accuracy of MRI, with a focus on advanced imaging modalities such as Dynamic
Contrast-Enhanced MRI (DCE-MRI) and Diffusion-Weighted Imaging (DWI), in
differentiating benign from malignant brain lesions. Over a one-year period
(2023–2024), MRI scans of 129 patients were reviewed. Results demonstrated
high sensitivity (92%) and specificity (86%) for malignant tumor detection.
Enhanced diagnostic precision was achieved through DCE-MRI and DWI, which
improved tissue characterization by assessing perfusion dynamics and cellular
density. These findings support the vital role of MRI in early detection, treatment
planning, and prognosis evaluation in neuro-oncology.
Keywords
: MRI, Brain Tumors, DCE-MRI, DWI, Glioblastoma,
Meningioma, Diagnosis, Neuroimaging, Uzbekistan, Tumor Perfusion, Tumor
Cellularity
Aim: The primary aim of this study was to evaluate the diagnostic utility of
Magnetic Resonance Imaging (MRI) in identifying and characterizing brain
tumors in a clinical setting in Uzbekistan. Specific objectives included assessing
https://biti.uz/konferensiya/konferensiya2025/index.html
21 апреля 2025 г.
402
the effectiveness of MRI in differentiating between benign and malignant
intracranial neoplasms and determining the added diagnostic value of advanced
imaging techniques—namely Dynamic Contrast-Enhanced MRI (DCE-MRI) and
Diffusion-Weighted Imaging (DWI). These modalities were chosen for their
ability to assess tumor vascularity, perfusion dynamics, and cellular density,
which are critical parameters in tumor grading and classification. The study also
aimed to establish the correlation between radiological findings and
histopathological results where available, thus reinforcing the role of MRI as a
reliable, non-invasive diagnostic tool in neuro-oncological practice.
Materials and Methods
:
This was a prospective, observational study
conducted between January 2023 and January 2024 at the Republican Specialized
Neurosurgery Scientific and Practical Medical Center, Tashkent, Uzbekistan. A
total of 129 patients (male: 43%, female: 57%), aged 3 to 73 years, who presented
with neurological symptoms indicative of intracranial masses, were included.
Patients were included in the study based on clinical suspicion of a brain tumor
following neurological assessment and provision of informed consent for
participation and imaging. All MRI scans were performed using a 1.5 Tesla
Siemens Magnetom Avanto system. The imaging protocol comprised
conventional sequences, including T1-weighted, T2-weighted, FLAIR, and
contrast-enhanced T1, along with advanced techniques such as dynamic contrast-
enhanced MRI (DCE-MRI) to evaluate perfusion characteristics and diffusion-
weighted imaging (DWI) to assess tissue cellularity. Image analysis was
conducted using Vidar DICOM software, and histopathological correlation was
obtained in cases where surgical excision or biopsy was performed.
Results
:
Out of 129 patients, benign tumors were identified in 30.7% of
cases, including meningiomas (20.9%), pituitary adenomas (2.3%), and
schwannomas or other benign types (7.5%), while malignant tumors accounted for
38.6%, comprising diffuse astrocytomas (16.3%), glioblastomas (13%), and
anaplastic ependymomas or metastases (9.3%). MRI demonstrated strong
https://biti.uz/konferensiya/konferensiya2025/index.html
21 апреля 2025 г.
403
diagnostic performance with a sensitivity of 92%, specificity of 86%, positive
predictive
value (PPV) of 89%, and negative predictive value (NPV) of 88%.
Advanced imaging techniques further enhanced
diagnostic accuracy: DCE-MRI
achieved a sensitivity of 92% for malignant and
85% for benign tumors, with
specificity rates of 86% and 88%, respectively, and provided detailed perfusion
maps and permeability indices (Ktrans, Ve). Additionally, diffusion-weighted
imaging (DWI) effectively differentiated high-grade gliomas characterized by
lower apparent diffusion coefficient (ADC) values from low-grade tumors,
showing a strong correlation with tumor cellularity (Zhou M et al., 2014, p. 1900;
Mabray MC et al., 2015, p. 10).
Conclusion
:
This study underscores the pivotal role of Magnetic Resonance
Imaging (MRI) in the diagnosis, classification, and clinical evaluation of brain
tumors in a clinical setting in Uzbekistan. The findings demonstrate that MRI,
particularly when enhanced with advanced imaging modalities such as Dynamic
Contrast-Enhanced MRI (DCE-MRI) and Diffusion-Weighted Imaging (DWI),
provides high diagnostic sensitivity and specificity in distinguishing between
benign and malignant intracranial neoplasms.The high-resolution anatomical
detail offered by conventional MRI sequences facilitates precise localization and
morphological assessment of tumors, while DCE-MRI contributes critical
information about tumor perfusion and vascular permeability parameters that are
often elevated in malignant lesions. Furthermore, DWI, through analysis of tissue
diffusion characteristics and Apparent Diffusion Coefficient (ADC) values,
effectively differentiates high-grade gliomas from low-grade or benign tumors,
reflecting differences in tumor cellularity.The integration of these advanced
imaging techniques not only improves diagnostic accuracy but also enhances
preoperative planning and prognostic evaluation. For instance, glioblastomas
identified in a significant portion of malignant cases displayed characteristic
imaging features on both DCE-MRI and DWI that correlated well with
histopathological findings. Similarly, meningiomas and other benign lesions were
https://biti.uz/konferensiya/konferensiya2025/index.html
21 апреля 2025 г.
404
more reliably diagnosed based on their perfusion profiles and diffusion
characteristics.Importantly, the study highlights the clinical utility of a multimodal
MRI approach in resource-constrained settings, demonstrating that even with 1.5
Tesla systems, high-quality diagnostic imaging can be achieved. This has
substantial implications for early diagnosis and timely intervention, particularly in
regions where access to histopathology may be limited or delayed.Looking
forward, the incorporation of artificial intelligence (AI)-driven image analysis,
machine learning algorithms, and radiomic feature extraction holds promise for
further refining diagnostic workflows. These technologies could enable automated
lesion characterization, risk stratification, and prediction of treatment response
,
thereby personalizing neuro-oncological care.In conclusion, MRI augmented by
DCE-MRI and DWI is a reliable, non-invasive, and indispensable modality in the
diagnostic armamentarium for brain tumors. Its continued development and
clinical integration will play a crucial role in enhancing outcomes for patients with
intracranial neoplasms in Uzbekistan and beyond.
References
1.
Osborn AG.
Diagnostic Imaging: Brain
, 3rd ed. Elsevier; 2016. pp. 47–
72.
2.
Stupp R, et al. Radiotherapy plus concomitant and adjuvant
temozolomide for glioblastoma.
N Engl J Med.
2005;352(10):987–996.
3.
Zhou M, et al. DCE-MRI and DWI in differentiating glioma grade.
AJNR
Am J Neuroradiol.
2014;35(10):1899–1905.
4.
Ferlay J, et al. Global cancer statistics 2020: GLOBOCAN estimates of
incidence and mortality.
CA Cancer J Clin.
2021;71(3):209–249.
5.
Mabray MC, Barajas RF Jr, Cha S. Modern brain tumor imaging.
Brain
Tumor Res Treat.
2015;3(1):8–23.
6.
Cha S. Perfusion MR imaging: basic principles and clinical applications.
Magn Reson Imaging Clin N Am.
2003;11(3):403–413.
7.
Essig M, et al. Perfusion MRI: the five most frequently asked clinical
questions.
AJR Am J Roentgenol.
2013;200(1):24–34.
8.
Law M, et al. High-grade gliomas and solitary metastases:
differentiation by using perfusion and proton spectroscopic MR imaging.
Radiology.
2003;222(3):715–721.
